An integrated therapeutic approach to sickle cell disease management beyond infancy.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26956
Abstract: Hydroxyurea, the first approved drug for sickle cell disease, decreases sickle hemoglobin polymerization by inducing fetal hemoglobin. Its effects in young children are excellent; responses in adults are variable and not curative. The goal of… read more here.
Keywords: cell disease; sickle; sickle cell; sickle hemoglobin ... See more keywords
Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease.
Sign Up to like & getrecommendations! Published in 2022 at "Biomacromolecules"
DOI: 10.1021/acs.biomac.2c00671
Abstract: The molecular origin of sickle cell disease (SCD) has been known since 1949, but treatments remain limited. We present the first high-throughput screening (HTS) platform for discovering small molecules that directly inhibit sickle hemoglobin (HbS)… read more here.
Keywords: drug discovery; sickle hemoglobin; sickle; cell disease ... See more keywords
The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2017.1395279
Abstract: ABSTRACT Introduction: Renal dysfunction is among the most common complication of sickle cell disease (SCD), from hyposthenuria in children to progression to overt chronic kidney disease (CKD) in young adults. Emerging evidence now suggests that… read more here.
Keywords: sickle hemoglobin; related nephropathy; disease; hemoglobin related ... See more keywords